The medical uses of Cannabis sativa preparations (hashish, marijuana, bhang) can be traced back to the first medical documents in old Asiatic medicine, 4000 years ago (1). However, the recreational use of these preparations is probably older. Throughout history there are testimonies describing their utilization, such as Herodotus' descriptions of the ritual use of cannabis by the Scythians, the medieval cavalry created by The Old Man of the Mountain (The Hashishins), and the 20th century images of the rock concerts of the 1960s. From the 1001 Arabian Nights to the short tales of Cornell Woolrich, the literature is also full of descriptions of the disruptive effects of cannabis on perception, mood, memory, and cognition (1, 2). Thirty-five years ago marijuana was a pharmacological mystery. In 1964 the isolation of the active constituents of hemp, the psychoactive cannabinoids described by Gaoni and Mechoulam (3), allowed the scientific community to unravel the myriads of pharmacological effects associated with cannabis administration, summarized in Fig. 1 .
Our knowledge of the pharmacological basis of the activity of cannabis started, then, with the isolation and synthesis of ⌬ 9 -tetrahydrocannabinol (THC), its main psychoactive constituent (3). Administration of THC to laboratory animals resulted in a characteristic pharmacological profile (2), which was mimicked by synthetic analogs developed thereon (2, 4). Many of these synthetic compounds included isomers that displayed a marked enantioselectivity (4). These highly enantioselective compounds were used by the group of Allyn Howlett in 1988 to identify a brain cannabinoid receptor (CB 1 , 5), whose neuropharmacology (6-11), anatomical distribution (12, 13), and molecular cloning (14) were rapidly achieved. The identification of the first proposed endogenous ligand, anandamide (15), and its main synthesis and degradatory pathways followed rapidly (16-21), together with the analysis of its pharmacological activity (22-27). The first CB 1 cannabinoid receptor antagonist was described in 1995 (28), allowing the further exploration of the functionality of the anandamide-CB 1 signaling system. Recent findings include the description of new effectors (7-11), the isolation of new endogenous ligands such as 2-arachidonylglycerol (29-31) and the routes for its synthesis and degradation (32), as well as the identification of a selective anandamide uptake system (33). From these findings, summarized in Table 1 , it is evident that during the past 10 years a real revolution has occurred in the understanding of the neurobiological processes underlying the actions of the psychoactive constituents of C. sativa, a revolution comparable to that in the pharmacology of opiates derived from the identification of the opiate receptors and the endogenous opioid peptides.
Based on these discoveries, today we can talk about the existence in the brain of an endogenous cannabinoid system, or endocannabinoid system, modeled in Fig.  2 . It is composed of at least the brain cannabinoid receptor (CB 1 , (5)), the proposed endogenous ligands anandamide (15) and 2-arachidonylglycerol (29, 31), the biochemical pathways for their synthesis and degradation (16) (17) (18) (19) (20) (21) 32) , and the anandamide uptake system (33). The great and continuously expanding advances in the cannabinoid field demand an integrative analysis of the neurobiology of this signaling system, from the molecular to the cognitive level, which has been the main aim of the present issue of Neurobiology of Disease.
In this monograph we have tried: (1) to give an
